Digestive and Liver Disease

Papers
(The median citation count of Digestive and Liver Disease is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?84
Pharmacologic venous thromboembolism prophylaxis is not associated with post sphincterotomy bleeding after endoscopic retrograde cholangiopancreatography67
Improvement of clinical parameters in HDV patients with advanced compensated cirrhosis treated with Bulevirtide monotherapy for 48 weeks57
The burden of HDV infection: A ten-years’ experience of a sicilian tertiary centre of liver disease57
Author's Reply: Comment on “Analysis of exposome and genetic variability suggests stress as a major contributor for development of pancreatic ductal adenocarcinoma”51
Faecal calprotectin-based strategy for long-term monitoring of patients with Crohn's disease without or with mild endoscopic postoperative recurrence47
Prevalence and outcomes of arthritis in pediatric IBD: A multicenter study from the Italian Society of Pediatric Gastroenterology Hepatology and Nutrition44
Innovative imaging for gastric cancer: Spectral CT and HRR41
FLIP identifies LES reduced distensibility as unexplained cause of dysphagia in a patient with hiatal hernia40
A new endoscopic tumor grading for rectal neuroendocrine tumors: Correlation of vascular pattern with histopathology39
“Artificial histology” in colonic Neoplasia: A critical approach34
Utilizing both IgA tissue transglutaminase and IgG-deamidated gliadin peptide antibodies offers accurate celiac disease diagnosis without duodenal biopsy32
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosin-kinase inhibitors: a real-world analysis32
Types, behaviour and therapeutic requirements of inflammatory pouch disorders: Results from the RESERVO study of GETECCU31
NOSTRIN is an emerging positive regulator of decompensated cirrhotic patients with portal hypertension31
Current management of hepatobiliary malignancies between centers with or without a liver transplant program: A multi-society national survey30
Predictors of esophago-gastric varices and variceal bleeding in patients receiving atezolizumab/bevacizumab for unresectable hepatocellular carcinoma29
Author's Reply: “Dairy-Rich diets: A promising strategy for reducing the risk of metabolic liver disease”29
Autoimmunity in chronic HDV infection: results from the HDV Describe study cohort28
Anticoagulation in Patients with Liver Cirrhosis and Portal Vein Thrombosis28
One-year changes in alt and lsm, not in cap, predict long-term liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease28
Duodenal organoids from patients with MASLD-cirrhosis display impaired mitochondrial energy metabolism and antioxidant defense28
Ultrasound muscular thickness-based model to identify sarcopenia in patients with portal hypertension (PH): a cross-sectional single-center observational study27
Prognostic role of endoscopic ultrasound guided direct portal pressure gradient measurement in porto-sinusoidal vascular disorder27
AI-AD score: a novel Machine Learning-based model for predicting Acute Liver Decompensation progression – a prospective observational study27
Management of ascites in elderly patients with cirrhosis: results of an Italian survey26
Relationship between recipient/donor features and liver stiffness measurement in the first year after liver transplantation26
Rectus femoris cross sectional area predicts 90-day readmission in patients hospitalized for an acute decompensation of cirrhosis25
Mri-based clinical-radiomics analyses of colorectal liver metastases to predict tumor growth patterns by machine learning approach23
MASLD and FIB4 are independent predictors of major adverse liver outcomes and cardiovascular events in type 2 diabetes: findings from a single-center cohort using AI-driven machine learning23
Liver transplants in untreated vs Bulevirtide-treated patients with chronic Hepatits Delta: a cross-sectional, intrahepatic analysis23
Coronary angiography in liver transplant work-up: report from a large multicenter Italian cohort23
Assessing perilipin-2 as a liver-specific biomarker: lack of correlation between cardiac damage and its levels in heart failure patients23
The changing scenario in hepatocellular carcinoma management: the Niguarda experience23
Enterobius vermicularis infection mimicking liver malignancy23
Treatment of portal hypertension through transjugular intrahepatic portosystemic shunt (TIPS) in patients with porto-sinusoidal vascular disease (PSVD)22
Oncostatin M contributes to liver steatosis in experimental conditions of Metabolic dysfuntion - Associated Steatotic Liver Disease22
Thrombus generation under flow conditions in patients with cirrhosis and thrombocytopenia: the CirTAS-study21
Exploring the impact of mitochondrial biomarkers on HCC risk according to etiologic drivers: a multicenter study21
Oncostatin M modulates the biology of cholangiocarcinoma cells and the tumor microenvironment21
Strategies to enhance Natural Killer cell response in Hepatocellular Carcinoma: The role of TGFβ in NK-Cells (dys)function and plasticity21
Assessing the diagnostic accuracy of ChatGPT-4 in the histopathological evaluation of liver fibrosis in metabolic dysfunction-associated steatotic liver disease21
Patients with cirrhosis and ascites treated with long-term albumin: An integrated management proposal based on a real-life study21
Quantification of plasma HDV RNA in untreated and Bulevirtide-treated patients with CHD: a comparison between Robogene 2.0, Eurobioplex EBX071 and Altostar20
Prevalence of steatotic liver disease and steatohepatitis in a population of healthy workers20
Thrombopoietin receptor agonists before elective invasive procedures in cirrhotic patients with thrombocytopenia: ready to start?20
Differential patterns of HBV RNA and HBcrAg levels in a large european cross-sectional study of untreated patients with chronic Hepatitis Delta20
Factors associated with prior acute pancreatitis episodes20
Mapping the hepatic mtDNA genomic landscape in patients with MASLD: The Era of GPT-4 Artificial Intelligence20
Giant gastric myxoid epithelioid gastrointestinal stromal tumor19
Metastatic hepatocellular carcinoma cured by exclusive systemic antiangiogenic therapy: Two cases along with tumor molecular profiles19
Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study19
Artificial intelligence-assisted colonoscopy to identify histologic remission and predict the outcomes of patients with ulcerative colitis: A systematic review19
Association between remnant cholesterol and metabolic dysfunction-associated steatotic liver disease in the elderly19
[¹¹C] choline as a potential PET/CT biomarker of liver cirrhosis: A prospective pilot study19
Reply to: “Inflammatory bowel disease epidemiology data from a prospective registry in Córdoba, Argentina: Raising the bar for future studies in Latin America”.18
OC.09.6 PREDICTIVE VALUE OF MILAN ULTRASOUND CRITERIA IN ULCERATIVE COLITIS: A PROSPECTIVE OBSERVATIONAL COHORT STUDY18
T.03.2 EXPLORING A NOVEL COMPOSITE DIAGNOSTIC TOOL USING NON-CONTRAST EUS ENHANCED CYST WALL MICROVASCULAR IMAGING AND CYST FLUID ANALYSIS TO DIFFERENTIATE PANCREATIC CYSTIC NEOPLASMS18
Subepithelial lesions in the distal esophagus18
Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis18
OC.10.3 LUMEN-APPOSING METAL STENTS FOR EUS-GUIDED DRAINAGE OF WALLED-OFF PANCREATIC NECROSIS: RESULTS OF A LARGE MULTICENTER COHORT18
Editorial Board18
Bacterial infections as a risk factor for non-neoplastic portal vein thrombosis development in cirrhotic patients18
OC.10.8 DISHEVELLED-ASSOCIATED ANTAGONIST OF B-CATENIN 2 (DACT2) IN PANCREATIC DUCTAL ADENOCARCINOMA18
T.04.1 EUS-GUIDED GASTROENTEROSTOMY VERSUS ENTERAL STENTING FOR FRAILER PATIENTS WITH MALIGNANT GASTRIC OUTLET OBSTRUCTION: A MATCHED PROSPECTIVE COMPARISON17
T.03.5 EFFECT OF ENVIRONMENTAL BISPHENOL A EXPOSURE ON TRAINED IMMUNITY-RELATED PATHWAYS IN NON-ALCOHOLIC FATTY LIVER DISEASE: A PRELIMINARY OBSERVATION17
OC.09.5 LONG-TERM EFFECTIVENESS OF USTEKINUMAB IN PATIENTS WITH REFRACTORY CROHN’S DISEASE: A MULTICENTER REALLIFE STUDY17
AF.11 BLACK ESOPHAGUS AND SEPTIC SHOCK IN ELDERLY PATIENT: A CASE REPORT17
T.05.10 CLINICAL HETEROGENEITY OF ADULT COELIAC DISEASE ACCORDING TO THE AGE AT ONSET: AN ITALIAN MULTICENTRIC STUDY17
T.04.6 EFFECTIVENESS OF ARTIFICIAL INTELLIGENCE FOR COLONOSCOPY ON ADENOMA AND POLYP MISS RATE: A METAANALYSIS OF TANDEM RCTS17
AF.5 COMPARISON OF CORPUS MUCOSA HISTOLOGICAL PARAMETERS BETWEEN PATIENTS WITH AUTOIMMUNE ATROPHIC GASTRITIS AND MULTIFOCAL ATROPHIC GASTRITIS BEYOND HELICOBACTER PYLORI INFECTION17
T.10.4 INTESTINAL ULTRASONOGRAPHY PROFILING OF PATIENTS WITH CROHN'S DISEASE PREDICTS LONG TERM CLINICAL REMISSION16
AF.77 IRRITABLE BOWEL SYNDROME AND WORK ABILITY IN HEALTH WORKERS EXPOSED TO OCCUPATIONAL STRESS16
T.11.10 PERFORMANCE OF DIGITAL SINGLE-OPERATOR CHOLANGIOSCOPY IN THE VISUAL INTERPRETATION OF INDETERMINATE BILIARY STRICTURES: RESULTS FROM A SINGLECENTER RETROSPECTIVE REAL-LIFE STUDY16
AF.33 COMPLIANCE ASSESSMENT TO MICRONUTRIENT SUPPLEMENTATION AFTER BARIATRIC SURGERY: RESULTS FROM AN ITALIAN INTERNET-BASED SURVEY16
AF.66 VEDOLIZUMAB INDUCED LIVER INJURY: A RARE BUT MEANINGFUL CONDITION16
AF.83 USEFULNESS OF ELASTOMETRY IN EVALUATING THE EXTENTS OF LIVER FIBROSIS AND RISK OF NON HEPATIC COMPLICATION IN NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN DIABETIC PATIENTS TYPE 2 (DM2)16
AF.96 MODELING HEPATOCELLULAR CARCINOMA CELLS DYNAMICS BY SEROLOGICAL AND IMAGING BIOMARKERS TO EXPLAIN COMPLETE RESPONSE TO SORAFENIB16
AF.70 COLONOSCOPY IN DIVERTICULAR DISEASE BLEEDING: WHEN AND HOW TO DO IT16
AF.82 THE ROLE OF THE PNPLA3, TM6SF2 AND MBOAT7 GENETIC VARIANTS IN THE RESPONSE TO NUTRACEUTICAL THERAPY FOR NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS16
T.11.7 THE PROGNOSTIC ROLE OF RADIOMICS IN GASTRO-ENTEROPANCREATIC NEUROENDOCRINE TUMORS16
T.12.1 A LATE HEMATOMA AFTER ENDOSCOPIC FULL-THICKNESS RESECTION OF THE APPENDICEAL ORIFICE: WHAT WE SHOULD LEARN FROM PREOPERATIVE ANATOMICAL ASSESSMENT: A CASE REPORT15
AF.111 AUGMENTED REALITY APPLIED TO DIGESTIVE ENDOSCOPY15
T.12.8 GENDER IMPACT TO ENDOSCOPIC SLEEVE GASTROPLASTY OUTCOMES15
V.01.4 ENDOSCOPIC TREATMENT OF ANASTOMOTIC STENOSIS IN A WOMAN WITH MARSUPIALIZATION FOR GASTRO-DUODENAL DUPLICATION AND PANCREAS DIVISUM15
AF.128 ENDOSCOPIC MUCOSAL RESECTION (EMR) AND ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) IN THE MANAGEMENT OF LARGE (≥20 MM) NON-PEDUNCOLATE COLORECTAL LESIONS (LNPCLS): EXPERIENCE FROM AN ITALIAN REFERRA15
AF.98 ERCP THROUGH SURGICAL GASTROSTOMY IN PATIENTS WITH PREVIOUS GASTRIC BY-PASS: A CASE REPORT15
AF.112 ENDOROTOR-BASED ENDOSCOPIC NECROSECTOMY IN COMPLICATED WALLED-OFF PANCREATIC NECROSIS: A CASE REPORT15
V.01.7 COMPLETE INTRA-PERITONEAL MALDEPLOYMENT OF A LAMS DURING EUS-GEA FOR MGOO: RESCUE RETRIEVAL WITH PERITONEOSCOPY THROUGH NOTES15
AF.100 RITUXIMAB FOR INDUCTION OF REMISSION IN IGG4-RELATED PANCREATO-BILIARY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS15
AF.113 OUTCOMES IN EFTR WITH FTRD-SYSTEM: WHEN PATIENT SELECTION IS CRUCIAL15
V.02.2 ENDOSCOPIC TREATMENT OF GASTRIC PERFORATION, BILIODIGESTIVE ANASTOMOSIS DEHISCENCE AND JEJUNAL STUMP LEAK AFTER RADICAL PANCREATECTOMY15
Application of Machine Learning Model-3P to Predict Portal Hypertension in Patient with Hepatocellular Carcinoma14
Inhibition of the Extracellular Signal-Regulated Kinase ERK5 induces an increased expression of the Epidermal Growth Factor receptor and sensitizes hepatocarcinoma cells to gefitinib14
AF.142 ADEQUACY OF EUS-FNB WITH MACROSCOPIC ON-SITE EVALUATION (MOSE) FOR GI SUBEPITHELIAL LESIONS: ARE TWO NEEDLE PASSES ENOUGH?14
AF.156 PERFORMANCE OF HOT-SPAXUSTM IN TREATING ACUTE AND CHRONIC CHOLECISTITIS: A RETROSPECTIVE MULTICENTER STUDY14
OC.07.8 EUS-GUIDED ILEAL-ASCENDING COLON ANASTOMOSIS WITH WATER-FILLED TECHNIQUE FOR PALLIATION OF CIECAL COLON CANCER INVADING THE ILEO-CIECAL VALVE14
The impact of metabolic risk factors on gender differences in HCC development and treatment allocation14
AF.139 PERFORMANCE OF EUS-GUIDED MOSE-AIDED TISSUE ACQUISITION FOR STRICTURES OF THE COMMON BILE DUCT14
AF.145 LINEAR EUS ACCURACY IN GASTRIC CANCER PREOPERATIVE STAGING: A RETROSPECTIVE MULTICENTRIC STUDY14
Prevalence of portal vein thrombosis in non-alcoholic fatty liver disease: a meta-analysis of observational studies14
Efficacy and safety of atezolizumab/bevacizumab for hepatocellular carcinoma in a real-life prospective cohort: data from a multicenter collaborative study14
De-novo occurrence of portal vein thrombosis in patients with HCV-related cirrhosis after sustained virological response: medium to long term observations from the ongoing PITER cohort14
AF.144 EUS-GASTROENTERO ANASTOMOSIS IN BENIGN GASTRIC OUTLET OBSTRUCTION DUE TO LARGE DUODENAL DIVERTICULA14
AF.146 RADIAL EUS: READY FOR RETIREMENT?14
Outcomes of three lines Atezolizumab plus Bevacizumab-based sequential treatment for hepatocellular carcinoma: a simulation model14
Stereotactic body radiation therapy (SBRT) for HCC treatment: a single institution experience13
Incidental findings of anti-mitochondrial antibodies without evidence of Primary Biliary Cholangitis13
A Markov model unveiling the impact of Resmetirom on the natural history of MASLD patients with baseline significant or severe liver fibrosis13
Does HLA-G play a role in PBC?13
Irisin alleviates liver oxidative stress in non-obese, non-diabetic individuals with Non-Alcoholic Fatty Liver Disease13
Evaluation of allelic frequency and genetic risk score of non-alcoholic fatty liver disease in a population of Southern Italy13
Bulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis13
Steroidomic profiles across the spectrum of liver damage in non-alcoholic fatty liver disease13
Spleen stiffness measurement improves non-invasive prediction of clinically significant portal hypertension in primary biliary cholangitis13
Diagnostic and prognostic role of urinary Neutrophil Gelatinase-associated Lipocalin in patients with cirrhosis and acute kidney injury13
The impact of bacterial infections on cirrhosis complications in a cohort of cirrhotic patients in a northern Italian hospital13
Prevalence of HCV infection in a nursing home: the unknown submerged population13
A new high-throughput HBV integration sequencing approach shows that mitochondrial DNA is frequently targeted by virus integration in liver cells with active HBV replication13
Hepatic sarcoidosis:an Italian multicenter study13
The IMPROVEMENT project: first report of the global liver transplant activity13
Multiple liver lesions leading to urgent referral12
Identification of key predictors of significant weight loss in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a multicentre study12
Impact of ISO score on oncological outcomes and survival in liver transplant candidates with hepatocellular carcinoma12
Characteristics and management of hepatocellular carcinoma (HCC) in Sicily: first results of the HCC Sicily Multidisciplinary Network12
Safety and Effectiveness of anticoagulation in patients with cirrhosis listed for liver transplantation: a single center observational study12
Liposomal doxorubicin targeted with the Fab' of atezolizumab as a novel strategy against HCC12
Outcomes of Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced hepatocellular carcinoma in the era of immunotherapy: A real-life comparison with best supportive care12
Prophylaxis of HBV-recurrence after liver transplantation in patients with HCC: Risk of HCC recurrence from a large, multicentre retrospective study from Italy12
Whole blood thrombin generation improves the understanding of cirrhotic coagulopathy and predicts clinical outcomes in patients with cirrhosis: a prospective cohort study12
Tiny but powerful: platelets behaviour in metabolic dysfunction-associated steatotic liver disease and its evolution to liver cirrhosis12
MerTK-expressing macrophages promote the malignant features of cholangiocarcinoma cells12
OC-02Activation of Liver X Receptor-α in the gut protects against liver injury in nonalcoholic steatohepatitis (NASH)12
Impact of acute on chronic liver failure (aclf) superimposed to alcoholic cirrhosis: a single centre experience12
Changes in mean arterial pressure are inadequate to guide treatment with terlipressin and albumin in patients with hepatorenal syndrome - acute kidney injury12
Nash up, virus down: how is changing the waiting list for liver transplantation: a single center experience from Italy12
A modified Charlson Comorbidity Index to improve management of patients with hepatocellular carcinoma: a step towards precision medicine12
Comparative efficacy and safety of resection techniques for treating 6 to 20mm, nonpedunculated colorectal polyps: A systematic review and network meta-analysis12
Prevalence and clinical outcomes of different forms of renal dysfunction in patients hospitalized for decompensated cirrhosis: focus on acute kidney disease. A prospective observational study12
Unravelling the role of mitochondrial dysfunction in the switching towards progressive MASLD by exploiting an AMLN diet-fed mouse model12
Non-psychedelic doses of psilocybin as a novel therapeutic approach for MASLD12
Impact of laparoscopic liver resection for access to the waiting list of a single regional liver transplant center in southern Italy: entry and dropout flows’ analysis12
Impact of bacterial infections prior liver transplantation on post-transplant outcomes in patients with cirrhosis12
Cholestasis impacts on performance of non invasive tests for ruling out high-risk esophageal varices in patients with primary biliary cholangitis and compensated advanced chronic liver disease12
Placement of a trans-jugular intrahepatic portosystemic shunt (TIPS) modifies the expression of soluble mediators by circulating monocytes12
Editorial Board12
Author`s reply: Effect of exercise-based interventions in nonalcoholic fatty liver disease: A systematic review with meta-analysis12
T.04.5: COMPARISON OF SUBCUTANEOUS AND INTRAVENOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE SHOWED NO DIFFERENCES IN IMMUNOGENICITY OR TREATMENT PERSISTENCE AT ONE YEAR11
T.07.10: BACTERIAL AND FUNGAL INFECTIONS INACLF: PREVALENCE AND IMPACT ON PATIENT MORBIDITY AND MORTALITY11
V.01.1: EUS-HEPATICODUODENOSTOMY WITH LAMS FOR RECANALIZATION OF A ROUX-EN-Y HEPATICOJEJUNOSTOMY STENOSIS11
V.02.1: KNIFE-ASSISTED INCISION FOR RESTORING ESOPHAGEAL LUMEN AFTER SURGICAL EXCLUSION11
OC.09.5: INCIDENTAL ENDOSCOPIC REMOVAL OF A RECTAL NEUROENDOCRINE TUMOR: WHAT TO DO?11
OC.09.1: EFFICACY AND SAFETY OF HYBRID ARGON PLASMA COAGULATION TECHNIQUE IN PATIENTS WITH BARRETT'S ESOPHAGUS-RELATED DYSPLASIA: AN ITALIAN MULTICENTER PROSPECTIVE STUDY INITIAL RESULTS11
Trends in the age-related incidence of colon and rectal cancers in China, 2005–201511
V.01.4: TRANSSTOMAL EUS-GUIDED ILEOCOLOSTOMY FOR RELIEF OF MALIGNANT SMALL-BOWEL OBSTRUCTION11
T.01.2: DISTINCT PATHOPHYSIOLOGICAL AND THERAPEUTIC OUTCOME PATTERNS CHARACTERIZE PATIENTS WITH DOMINANT HEARTBURN, REGURGITATION OR CHEST PAIN11
OC.11.1: UNDERDILATION STRATEGY FOR TIPS PLACEMENT REDUCES INCIDENCE OF OVERT HEPATIC ENCEPHALOPATHY WITHOUT AFFECTING CLINICAL EFFICACY AND SURVIVAL: RESULTS OF A MULTICENTER PROSPECTIVE ITALIAN STUD11
T.03.8: TIMING OF LUMEN-APPOSING METAL STENTS REMOVAL IN PANCREATIC FLUID COLLECTIONS: COULD WE GO BEYOND?11
OC.04.9: PROMOTION OF PHYSICAL ACTIVITY WITH A MOBILE APP IS SUPERIOR TO PRESCRIPTION ALONE IN IMPROVING SYMPTOMS IN PATIENTS WITH IRRITABLE BOWEL SYNDROME: A RANDOMIZED CONTROLLED TRIAL11
BOC.04.2: TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY11
H. PYLORI INFECTION AFFECTS THE HER2-CDH1 INTERACTION11
Returning to endoscopy normality through the support of a new non-invasive faecal test based on microbial signatures11
T.07.7: CHARACTERISTICS AND MANAGEMENT OF HEPATOCELLULAR CARCINOMA (HCC) IN SICILY: FIRST RESULTS OF THE HCC SICILY MULTIDISCIPLINARY NETWORK11
T.12.2: THE LEVELS OF AFP, PIVKA-II AND GPC-3 SERUM BIOMARKERS AT DIAGNOSIS CORRELATE WITH HCC CLINICAL-PATHOLOGICAL FEATURES AND WITH OVERALL SURVIVAL11
T.09.3: HIGH RESOLUTION MANOMETRY ASSESSMENT IN EROSIVE REFLUX DISEASE11
T.11.1: MICRONUTRIENT NUTRITIONAL DEFICIENCIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN REMISSION FOLLOWING A LONG-TERM BIOLOGIC TREATMENT11
V.05.4: STENT-IN-STENT ANCHORED WITH METALLIC CLIPS TO TREAT RECURRENCE OF NEOPLASTIC ESOPHAGEAL STENOSIS11
V.05.1: EUS-GUIDED FINE NEEDLE BIOPSY OF A DUODENAL GIST: A CHALLENGE FOR ENDOSONOGRAPHERS11
T.04.4: CLINICAL OUTCOME AFTER CROHN'S DISEASE-RELATED SURGERY DIFFERENT FROM ILEO-COLONIC RESECTION11
OC.01.3: EVENING CHRONOTYPE CORRELATES WITH SEVERITY OF FUNCTIONAL DYSPEPSIA AND AFFECT SLEEP QUALITY11
OC.07.10: SARCOPENIA IS A RISK FACTOR OF POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE10
BOC.04.1: ANALYSIS OF IMMUNOLOGICALVARIABLES IN EX VIVO TOFACITINIB-TREATED HUMAN BIOPSIES FROM ACTIVE ULCERATIVE COLITIS PATIENTS TO PREDICT CLINICAL RESPONSE (THE AVATAR STUDY)10
OC.10.1: TOTALLY RETROGRADE ENDOSCOPIC THERAPY TO TREAT STRASBERG TYPE C BILE LEAKS: A RETROSPECTIVE SINGLE CENTER EXPERIENCE10
OC.16.12: PERFORMANCE EVALUATION OF HEPATIC VENOUS PRESSURE GRADIENT (HVPG) SCORE AS PREDICTOR TOOL OF LIVERRELATED EVENTS IN PATIENTS WITH ADVANCED CHRONIC LIVER DISEASE10
OC.17.2: ERIC, NEW VIRTUAL ASSISTANT FOR COLONOSCOPY: A PILOT STUDY10
OC.07.1: CROHN'S DISEASE PATIENTS WITH USTEKINUMAB-INDUCED REMISSION ARE CHARACTERIZED BY HIGH BASELINE P35 CYTOKINES SUBUNITS IN LPMC AND HIGH IL-23 RECEPTOR EXPRESSION IN THE LAMINA PROPRIA TH1 CELL10
OC.03.3: CAN CHAT GENERATIVE PRE-TRAINED TRANSFORMER (CHATGPT) BE AN AI-PROVIDED FRIEND OF THE IBD PATIENTS FOR FREQUENTLY ASKED QUESTIONS RELATED TO THEIR DISEASE MANAGEMENT? AN EVIDENCE- AND GUIDELI10
T.11.6: QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ON EXPERIMENTALTRIAL: ATERTIARY SINGLE-CENTER EXPERIENCE10
OC.02.8: ENDOSCOPIC SLEEVE GASTROPLASTY: CAN WE PREDICT ITS EFFICACY AT AN EARLY STAGE?10
OC.12.3: SAFETY AND EFFICACY OF MUSCULAR-TUNNELING PERORAL ENDOSCOPIC SEPTOTOMY (MT-POES) FOR THE TREATMENT OF ZENKER'S DIVERTICULUM10
OC.04.5: ARTIFICIAL INTELLIGENCE AND COLORECTAL NEOPLASIA DETECTION PERFORMANCES IN FIT+ PATIENTS: A METAANALYSIS AND SYSTEMATIC REVIEW10
OC.13.1: PREVENTABLE FACTORS OF POST-COLONOSCOPY COLORECTAL CANCER IN INFLAMMATORY BOWEL DISEASE PATIENTS10
OC.02.4: SMALL-BOWEL CANCER SURVEILLANCE WITH CAPSULE ENDOSCOPY IN A LARGE COHORT OF LYNCH SYNDROME PATIENTS FOR 20 YEARS10
OC.05.7: CHOLESTASIS IMPACTS ON PERFORMANCE OF NON INVASIVE TESTS FOR RULING OUT HIGH-RISK ESOPHAGEALVARICES IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND COMPENSATED ADVANCED CHRONIC LIVER DISEASE10
OC.03.8: EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHN'S DISEASE: 104-WEEK EXTENSION RESULTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL10
OC.16.10: FATTY LIVER IN IBD PATIENTS: FINDINGS FROM AN OBSERVATIONAL RETROSPECTIVE CROSS-SECTIONAL STUDY9
V.04.5: OVER THE SCOPE CLIPS: A RESCUE THERAPY FOR DUODENAL PERFORATION DUE TO BILIARY STENT MIGRATION9
T.08.7: THE EFFECTIVENESS OF THE ULCA QUESTIONNAIRE IN THE EVALUATION OF GASTROINTESTINAL INVOLVEMENT IN PATIENTS AFFECTED BY SYSTEMIC SCLEROSIS9
OC.15.5: POLIPROTECT IS AN EFFECTIVE TREATMENT TO MANAGE PPI DEPRESCRIBING. A RANDOMIZED CONTROLLED TRIAL (RCT) POST HOC ANALYSIS9
V.02.8: CASE REPORT: DIEULAFOY'S LESION DETECTION TRICKS AND TREATMENT9
V.02.5: THE APOLLO OVERSTITCH SUTURING SYSTEM IS THE LAST CHANCE FOR RECTAL BLEEDING AFTER COMPLICATED ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD)9
AF.7 USE OF PURASTAT® FOR POST-SPHINCTEROTOMY BLEEDING REFRANTORY TO SELF-EXPANDABLE METALLIC STENT (SEMS) PLACEMENT: A CASE REPORT9
Venous hepatic aneurysms9
Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn's disease9
Comparative efficacy of different techniques for colonic endoscopic submucosal dissection: A network meta-analysis of randomized controlled trials9
OC.18.12: THE OUTPATIENT MANAGEMENT IN GASTROINTESTINAL BLEEDING REDUCES THE RE-BLEEDING DURING THE TIME: A COHORT OBSERVATIONAL STUDY9
BOC.02.1: EFFICACY AND SAFETY OF FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF CLOSTRIDIOIDES DIFFICILE INFECTION: A 10-YEAR EXPERIENCE OF A LARGEVOLUME FMT CENTER9
OC.08.3: DUPILUMAB EFFICACY IN EOSINOPHILIC ESOPHAGITIS PERSISTS FOR HISTOLOGIC, SYMPTOMATIC, AND ENDOSCOPIC OUTCOMES REGARDLESS OF CONCOMITANT HIGH-DOSE PROTON PUMP INHIBITOR USE9
OC.08.4: ARTIFICIAL INTELLIGENCE TOOLS PREDICT EOSINOPHILIC ESOPHAGITIS IN ADULTS REPORTING DYSPHAGIA: DEVELOPMENT, EXTERNALVALIDATION, AND SOFTWARE CREATION FOR POINT-OF-CARE USE9
T.09.6: VALUE OF MULTIDETECTOR COMPUTED TOMOGRAPHY ANGIOGRAPHY IN SEVERE NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING: A RETROSPECTIVE STUDY IN A REFERRAL BLEEDING UNIT9
V.01.8: HEPATIC FASCIOLIASIS: A RARE CASE OF “FAKE” BILIARY GALLSTONES9
How macronutrients and pancreatic enzyme supplements dose variability affect fat, protein and starch absorption in children with cystic fibrosis9
Antitissue transglutaminase antibodies’ normalization after starting a gluten-free diet in a large population of celiac children-a real-life experience9
Right-sided diverticulosis is an independent risk factor for bleeding in patients admitted for diverticular disease9
Tofacitinib in ulcerative colitis – Small molecule but large effect9
T.06.3: PREVALENCE OF, AND MICROBIAL RISK FACTORS FOR, IRRITABLE BOWEL SYNDROME AND FUNCTIONAL DYSPEPSIA AFTER ACUTE GASTROINTESTINAL INFECTION: A SYSTEMATIC REVIEW AND META-ANALYSIS9
T.06.9: PT1 CANCER OF THE COLON AND RECTUM (CCR): RETROSPECTIVE EVALUATION AND FOLLOW-UP IN REAL PRACTICE9
T.11.9: BIOLOGICAL THERAPIES IN THE ELDERLY PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A SINGLE-CENTER EXPERIENCE9
T.12.6: HHV8-NEGATIVE EFFUSION-BASED LARGE B-CELL LYMPHOMA (EB-LBCL): A RARE CAUSE OF DIARRHEA AND ASCITES9
V.03.4: ENDOSCOPIC “UNROOFING” OF AN INTESTINAL LIPOMA9
AF.41 THE PROGNOSTIC VALUE OF ENDOSCOPIC MAYO SCORE 0 VERSUS 1 IN PATIENTS WITH ULCERATIVE COLITIS IN STEROID-FREE CLINICAL REMISSION: A SYSTEMATIC REVIEW AND METAANALYSIS9
Jejunal gastrointestinal stromal tumor with rectal lymph nodes metastases synchronous to intestinal adenocarcinoma: a possible common origin9
V.01.7: A LAPAROSCOPIC AND ENDOSCOPIC COOPERATIVE SURGERY (LECS) APPROACH FOR TREATMENT OF APPENDICEAL LESION IN PATIENTS WITH SERRATED POLYPOSIS SYNDROME (SPS)9
Combined oral contraceptives are associated with increased risk of developing gastroparesis in pre-menopausal women9
OC.02.4 WHEN ACHALASIA PATIENTS RELAPSE AFTER LAPAROSCOPIC MYOTOMY, COMPLEMENTARY PNEUMATIC DILATIONS REPRESENT AN EFFECTIVE AND SAFE TREATMENT8
AF.61 PROSPECTIVE, OBSERVATIONAL STUDY OF PROPHYLACTIC VEDOLIZUMAB TREATMENT IN PREVENTING POSTOPERATIVE RECURRENCE (POR) IN HIGH-RISK CROHN’S PATIENTS8
T.05.5 A COMPARISON OF PCA-POSITIVE VS PCA-NEGATIVE AUTOIMMUNE ATROPHIC GASTRITIS PATIENTS8
OC.05.7 BLINDED ORAL CHALLENGES WITH LACTOSE AND PLACEBO ACCURATELY DIAGNOSE LACTOSE INTOLERANCE: A REAL-LIFE STUDY8
OC.04.7 LONG-TERM EFFICACY AND SAFETY OF OBETICHOLIC ACID IN PATIENTS WITH PBC FROM THE POISE TRIAL GROUPED BIOCHEMICALLY BY RISK OF DISEASE PROGRESSION8
AF.50 SAFETY AND CLINICAL EFFICACY OF THE DOUBLE SWITCH FROM ORIGINATOR INFLIXIMAB TO BIOSIMILARS CT-P13 AND SB2 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES (SCESICS): A MULTICENTER COHORT STUDY8
Individualized HBIG withdrawal in an historical cohort of liver transplant recipients in Italy8
OC.09.5 ALTERNATION OF MRI AND EUS IN PANCREATIC CANCER SCREENING COULD INCREASE DETECTION OF BOTH PANCREATIC AND EXTRA-PANCREATIC FINDINGS8
T.01.11 AN RC TRIAL COMPARING THE MUCOSAL PROTECTIVE AGENT (MPA) POLIPROTECT (NEOBIANACID®) (P) AND OMEPRAZOLE (O) IN THE TREATMENT OF HEARTBURN AND EPIGASTRIC PAIN/BURNING IN NON-EROSIVE REFLUX DISEA8
OC.06.2 ULTRASOUND EVALUATION OF PELVIC FLOOR DYNAMIC IN CONSTIPATED PATIENTS: A NEW APPROACH TO DIAGNOSE FUNCTIONAL DEFECATION DISORDERS8
OC.03.9 SPARING SPLENIC ARTERY: RADIOLOGICAL-ASSISTED DIRECT ENDOSCOPIC NECROSECTOMY USING ENDOROTOR8
OC.04.5 DISEASE ACTIVITY PATTERNS IN THE FIRST 5 YEARS AFTER DIAGNOSIS IN CHILDREN WITH CROHN'S DISEASE: A POPULATION-BASED STUDY8
AF.38 SHORT BOWEL SYNDROME IN ITALY, YET UNDERESTIMATED AND IN NEED OF INCREASED AWARENESS: PRELIMINARY REPORT FROM AN AIGO SURVEY8
AF.16 DIAGNOSTIC DELAY AND MISDIAGNOSIS IN EOSINOPHILIC ESOPHAGITIS8
T.03.3 THE INFLUENCE OF SUPERIMPOSED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-COV-2) LIFESTYLE CHANGES ON NON-ALCOHOLIC FATTY LIVER DISEASE EVOLUTION: A MATTER OF BODY COMPOSITION: A MULT8
OC.03.2 BILIOPANCREATIC ADVERSE EVENTS AFTER PANCREATICODUODENECTOMY: PRELIMINARY RESULTS OF ENDOSCOPIC MANAGEMENT WITH PEDIATRIC COLONOSCOPE8
Verona liver day: Data of liver health from the Arena8
OC.12.5 MYOSTEATOSIS IS NOT ASSOCIATED WITH COMPLICATIONS OR SURVIVAL IN HCC PATIENTS UNDERGOING TRANS ARTERIAL EMBOLIZATION8
OC.06.5 HIGH SMAD7 MARKS INFLAMMATION IN PATIENTS WITH CHRONIC POUCHITIS8
T.01.6 THE EFFICACY OF SIX-FOOD ELIMINATION DIET IS LOWER DURING POLLEN SEASON IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS SENSITIZED TO POLLENS8
OC.04.3 FIRST-LINE IMMUNE CHECKPOINT INHIBITOR-BASED SEQUENTIAL THERAPIES FOR ADVANCED HEPATOCELLULAR CARCINOMA: A RATIONALE FOR FUTURE TRIALS8
OC.04.1 SURGERY IN HIGH-RISK PAEDIATRIC CROHN'S DISEASE TREATED WITH UP-FRONT ANTI-TNF AGENTS AND LONG-STANDING BIOLOGIC THERAPY8
T.01.7 VACCINATION STATUS AND ATTITUDES TOWARDS VACCINES IN A COHORT OF PATIENTS WITH CELIAC DISEASE8
AF.3 QUALITY OF LIFE IN PATIENTS COMPLAINING OF UPPER GASTROINTESTINAL SYMPTOMS: A NATIONAL SURVEY IN PATIENTS ATTENDING GASTROENTEROLOGY CLINICS OF THE ITALIAN NHS: AN INTERIM ANALYSIS OF THE GUESS S8
AF.45 IBUS-SAS FOR CROHN’S DISEASE ULTRASOUND ACTIVITY: INITIAL VALIDATION AND RESEARCH OF THE OPTIMAL CUT-OFF SCORE8
Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: A single-center experience8
OC.09.4 PREVALENCE OF NAFLD (NON ALCOHOLIC FATTY LIVER DISEASE) IN INFLAMMATORY BOWEL DISEASE: THE ROLE OF METABOLIC FACTORS, INTESTINAL INFLAMMATION AND GENETIC PHENOTYPE8
AF.43 SOCIAL FUNCTIONING, WORK-PRODUCTIVITY AND PSYCHOLOGICAL ASSESSMENT IN A COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE: AN OBSERVATIONAL STUDY8
OC.10.3 INCREASED INTESTINAL PERMEABILITY IN CROHN'S DISEASE PATIENTS TREATED WITH TEDUGLUTIDE FOR SHORT BOWEL SYNDROME: PARADOXICAL OR BENEFICIAL EFFECT?8
OC.12.6 SINGLE-USE DUODENOSCOPES IN EXTREME CONDITIONS: ERCP IN LIVER TRANSPLANTED PATIENTS8
OC.06.4 DEMOGRAPHIC DIFFERENCES IN LEFT-TO-RIGHT SHIFT OF COLON CANCER OVER 25 YEARS: RESULTS FROM ROBUST ANALYSIS OF CANCER REGISTRY DATA8
OC.03.8 SAFE AND EFFICACY OF SINGLE CENTRAL ENDOSCOPIC ULTRASOUND GUIDED NEUROLYSIS OF CELIAC PLEXUS FOR PAIN RELIEF IN UNRESECTABLE PANCREATIC CANCER PATIENTS8
OC.14.2 LACK OF SEROCONVERSION FOLLOWING COVID-19 VACCINATION, BUT NOT TREATMENT, IS AN INDEPENDENT RISK FACTOR FOR BREAKTHROUGH SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA 8
Epidemiological and clinical profile of HDV infected people in care in Italy: Interim analysis from the ongoing PITER cohort7
PC.01.9 HYPOMETHYLATION OF LINE-1 IN SMALL BOWEL CARCINOMAS AND COELIAC DISEASE7
HBsAg kinetics during and after nucleos(t)ide analogues described by mathematical modeling7
0.26358103752136